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Abstract: Objective: To develop a highly sensitive LC-MS/MS (liquid chromatography-mass spectrometry/mass spectrometry) 
method applied to the detection and quantitation of UDCA (ursodeoxycholic acid) related substances such as CA (cholic acid), DCA 
(deoxycholic acid), CDCA (chenodeoxycholic acid) and LCA (lithocholic acid) in raw material and pharmaceutical formulation. 
Methods: The method was validated for specificity, linearity, accuracy, precision, robustness. A triple quadrupole mass detector was 
employed, equipped with an ESI (electrospray ionization) source operated in the negative ion mode. The chromatographic system 
consisted of a Symmetry C18 column (150 mm × 4.6 mm, id; particle size 5 µm) and methanol-acetonitrile-ammonium acetate (pH 7.6; 
10 mM) (40:40:20, v/v/v) as the mobile phase. The chromatographic conditions were 25 uL injection volume, flow rate of 0.4 mL/min 
and column temperature set at 35 °C. Key findings: The method requires a minimum sample amount and presents very low LOD 
(limits of detection) for CA (0.29 ng/mL), DCA (0.59 ng/mL), CDCA (0.13 ng/mL) and LCA (0.44 ng/mL) in comparison to LC 
methods coupled to different detectors like UV (ultraviolet), fluorescence and refractive index. Conclusions: The developed and 
validated LC-MS/MS method for the determination of UDCA and related substances in raw material and in a suspension was 
advantageous since it required a minimum sample amount. In turn, it could be used as a stability indicating method. 
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1. Introduction 
UDCA (Ursodeoxycholic acid), (3α, 7β- 
dihydroxy-5β-cholan-24-oic acid), also known as 
ursodiol, is a naturally occurring BA (bile acid). BAs 
are steroid compounds, hydroxyl derivatives of 
5β-cholan-24 oic acid [1]. Primary BA, CA (are cholic 
acid) and CDCA (chenodeoxycholic acid); secondary 
BA such as DCA (deoxycholic acid) and LCA 
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(lithocholic acid), all of them in 3ɑ-position, and 
UDCA (3β-position) (Fig. 1). UDCA is the epimer of 
CDCA (3ɑ-position), this structural modification 
transforms UDCA in a less hydrophobic, detergent and 
toxic BA [2]. Therefore, UDCA has been used as a 
therapeutic agent for the treatment of hepatobiliary 
disorders such as cholestasis, biliary dyspepsia, 
primary biliary cirrhosis and different cholestatic 
conditions [3, 4]. 
UDCA raw material is obtained from an ox-bile [4]. 
CDCA (a poorly tolerated BA), LCA and DCA cause 
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Fig. 1  Chemical structure of UDCA and related substances: DCA, CDCA, CA and LCA. 
 
hepatotoxicity, with LCA being the most toxic, all of 
them can be found as potential related substances [5] 
along with CA. The USP(United States Pharmacopeia) 
UDCA official monograph proposes an HPLC (high 
performance liquid chromatography) method coupled 
to a differential refractive index detector for its analysis 
in raw material and a TLC (thin layer chromatography) 
method for the evaluation of CDCA and LCA as its 
related substances [6]. Moreover, the EP (European 
Pharmacopoeia) UDCA monograph presents a TLC 
method for the analysis of related substances; CA, 
CDCA, LCA and other related BA like DCA [7]. Due 
to the low absorptivity of BA, high concentration is 
needed for UV (ultraviolet) detection and also for TLC.  
Moreover, several analytical methods applied to the 
evaluation of the UDCA related substances have been 
reported. Most of them describe HPLC coupled to 
various detectors: UV [5], electrochemical [8], 
prederivatization fluorescence [5, 9], evaporative light 
scattering [10] and refractive index [5, 11]. Another 
method such as CE (capillary electrophoresis) has also 
been applied [12-14]. In this sense, in a previous work, 
we developed CE-UV methods applied to 
determination of BA in pharmaceutical formulations as 
well as the evaluation of UDCA related substances [12, 
14]. Although CE methods were suitable for the 
analysis of BA in pharmaceutical formulations and raw 
material, they require high sample concentrations and 
CE is not common laboratory equipment.  
On the other hand, HPLC tandem mass spectrometry 
[15] is the methodology of choice for the analysis of 
BA in biological samples, especially HPLC-MS (mass 
spectrometry) and HPLC-MS/MS which provide high 
sensitivity and specificity [16]. 
The aim of this work was to develop and validate for 
the first time a highly sensitive HPLC tandem MS/MS 
method for the evaluation of UDCA related substances 
in raw material and pharmaceutical formulation as a 
stability indicating method. To our knowledge, there is 
no report in literature on the use of an LC-MS/MS 
method to the analysis of UDCA related substances, in 
raw material and pharmaceutical formulation. 
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2. Materials and Methods 
2.1 Chemicals and Reagents 
UDCA, CA, DCA, CDCA and LCA were supplied 
from Sigma Aldrich (St. Louis, MO, USA). UDCA raw 
material was supplied from Magel S.A. (Buenos Aires, 
Argentina). Methanol and acetonitrile were 
HPLC-grade, phosphoric acid and ammonium acetate 
were purchased from Merck (Darmstadt, Germany). 
Methylparaben (Nipagin), propylparaben (Nipasol) 
and xanthan gum were supplied from Magel S.A 
(Buenos Aires, Argentina). Ultrapure water was 
obtained by an EASYpureTM RF equipment (Barnstead, 
Dudubuque, IA, USA). All solutions were filtered 
through 0.45 µm nylon membrane (Micron Separations 
Inc., Westboro, MA, USA) and before use (with 
vacuum).  
2.2 Equipment and Chromatographic Conditions 
The LC-MS/MS analyses were performed on an 
Ultimate 3000 System HPLC system (Thermo Fisher 
Scientific, Inc, San Jose, CA, USA) coupled to TSQ 
Quantum AcessMax mass spectrometer (Thermo 
Fisher Scientific, Inc, San Jose, CA, USA). The LC 
was equipped with an autosampler, quaternary pump, 
mobile phase online degasser and a thermostatted 
column compartment. The chromatographic separation 
was carried out isocratically using a Symmetry C18 
column (150 mm × 4.6 mm, id; particle size 5 µm) 
supplied by Waters (Milford, Massachusetts, USA). 
The mobile phase consisted of 
methanol-acetonitrile-10 mM ammonium acetate 
(40:40:20, v/v/v). The flow rate was set at 0.6 mL/min. 
The column temperature was set at 40°C. The injection 
volume was 20 µL and the running time was 10 
minutes. 
The TSQ Quantum Access Max triple quadrupole 
mass spectrometer was equipped with an ESI 
(electrospray ionization) source and was operated    
in the  negative ion  mode. The  optimal values  for MS 
 
parameters were: 4,500 V for spray voltage, 60 and 45 
for sheath and auxiliary gas pressure, respectively, 
280 °C for capillary temperature and 53 eV for 
collision energy. Data acquisition was performed using 
Xcalibur 2.1 software (Thermo Fisher Scientific, Inc, 
San Jose, CA, USA). 
2.3. Preparation of Stock, Standard and Sample 
Solution 
2.3.1 Preparation of Stock and Standard Solutions 
Totally, 400 mg of UDCA was accurately weighed 
and transferred to a 100 mL volumetric flask and 
dissolved in methanol to give a stock solution 
concentration of 4 mg/mL. Stock solutions of CA, 
DCA, CDCA, all of 4 µg/mL and 1 µg/mL LCA, were 
prepared by appropriate dilution in 
methanol/acetonitrile (50:50). Standard solution 
containing UDCA (40 µg/mL), CA (0.2 µg/mL), DCA 
(0.1 µg/mL), CDCA (0.4 µg/mL) and LCA (0.02 
µg/mL) was prepared by appropriate dilution in mobile 
phase. 
2.3.2 Preparation of Sample Solution 
2.3.2.1 UDCA raw material.  
For the analysis of CA, DCA, CDCA and LCA 
related substances, approximately 400 mg of UDCA 
raw material was accurately weighed in a 100 mL 
volumetric flask and dissolved in methanol. A 1/10 
dilution was prepared in methanol/acetonitrile (50:50). 
This was further diluted with mobile phase to a final 
concentration of 40 µg/mL. 
2.3.2.2 Pharmaceutical suspension.  
The UDCA suspension was shaken vigorously by 
hand immediately before use. A total of 16 g was 
transferred to a 100 mL volumetric flask and filled up 
with methanol, sonicated for 5 min and centrifuged at 
15,000 rpm for 10 min to separate the insoluble 
components. A 1/10 dilution of the supernatant was 
prepared in methanol/acetonitrile (50:50). This was 
further diluted with mobile phase to a final 
concentration of 40 µg/mL. 
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2.4 Method Validation 
The developed method was validated according to 
ICH (International Council for Harmonisation) 
guidelines [17]. Parameters such as specificity, 
linearity, LOD (limits of detection) and LOQ (limits of 
quantification), precision, accuracy and robustness 
were tested. 
2.4.1 Specificity 
A blank of excipients of the pharmaceutical 
suspension was prepared to test specificity. 
2.4.2 Linearity, LOD and LOQ 
Linearity was assayed at five concentration levels 
for each related compound within the range of 50-625 
ng/mL for CA, 25-425 ng/mL for DCA, 50-800 ng/mL 
for CDCA and 10-115 ng/mL for LCA, where each 
concentration was injected by triplicate. Regression 
coefficients were obtained by plotting the average peak 
area versus concentration, using the least squares 
method. LOD and LOQ were determined in six 
replicates, as 3 and 10 times S/N, respectively. RSD 
(relative standard deviation) for peak area was 
calculated. 
2.4.3 Precision 
Precision was evaluated for intra-day (n = 6) and 
inter-day (n = 18) for CA (207 ng/mL), DCA (119 
ng/ml), CDCA (422 ng/mL) and LCA (21 ng/mL) 
under the conditions described in preparation of stock 
and standard solutions. Precision was determined as 
RSD for peak area and retention time. 
2.4.4 Accuracy 
Accuracy was calculated as recovery. Samples were 
prepared with all excipients present in the suspension, 
the active pharmaceutical ingredient and subsequently 
supplemented with CA, DCA, CDCA and LCA at three 
different concentration levels (related to limit values 
for each related substance): 80%; 100% and 120%, 
three replicates of each level. The 100% level is related 
to the limit value of each related substance, that is: not 
more than 0.5% for CA, not more than 0.25% DCA, 
not more than 1% and not more than 0.05% LCA. The 
RSD for each related substances area was calculated.  
2.4.5 Robustness 
Robustness was evaluated for flow rate (+/- 0.05 
mL/min), column temperature (+/- 2°C) and injection 
volume (+/- 1 µL). The effect on chromatographic 
parameters such as retention factor, tailing factor, RSD 
for CA, DCA, CDCA and LCA standard solution at 
207 ng/mL, 119 ng/mL, 422 ng/mL and 21 ng/mL, 
respectively, were evaluated. 
2.4.6 Related Substances Analysis 
The developed method was applied to the analysis of 
related substances in raw material and pharmaceutical 
suspension. Sample solutions were prepared according 
to preparation of sample solutions. Quantification of 
related substances was performed under the conditions 
described in equipment and chromatographic 
conditions. 
3. Results and Discussion 
3.1 Method Development  
The aim of this work was to develop an 
HPLC-MS/MS method for the detection and 
quantification of UDCA and related substances in raw 
material and suspension.  
The USP UDCA monograph describes CDCA and 
LCA as related substances, where each related 
substance limit should not be more than 1.5% w/w and 
0.05% w/w, respectively. At the same time, the 
European Pharmacopoeia refers to CA, DCA, CDCA 
and LCA as related substances, where each related 
substance limit should not be more than 0.5% w/w, 
0.25% w/w, 1.0% w/w and 0.1% w/w, respectively 
The chromatographic conditions were optimized to 
achieve good resolution, symmetric peak shapes and a 
short run time. The use of a Waters Symmetry C18 
column was more suitable for the analysis of BA as it 
provided better separation, especially sharper peaks as 
well as less retention time shift compared with other 
columns. The mobile phase consisted of a mixture of 
methanol: acetonitrile: 10 mM ammonium acetate 
(40:40:20). The proportion of organic solvent allows 
the elution of the analytes in adequate retention time. 
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Buffer concentration was an important factor to 
optimize. Higher concentrations of ammonium acetate 
could improve resolution, but with lower sensitivity. 
Therefore, 10 mM ammonium acetate was a good 
choice in terms of resolution and sensitivity. 
The mass detector was equipped with an ESI 
(electrospray ionization) source and was operated in 
the negative ion mode as BAs have an acidic group in 
their chemical structure. The operational conditions 
were optimized to obtain an efficient ionization 
(equipment and chromatographic conditions). 
A mix standard solution of UDCA, CA, DCA, 
CDCA and LCA was presented in Fig. 2. 
The parent-ion and product-ion pairs of UDCA, CA, 
DCA, CDCA and LCA were analyzed. The 
unequivocal identification of CA, DCA, CDCA and 
LCA was achieved using the product-ion (qualifier ion) 
and retention times. However, given that UDCA,  
DCA and CDCA have the same fragmentation  
pattern, the quantitation of CA, DCA, CDCA and  
LCA was made using the respective molecular ion 
(which is considered as the quantifier ion). 
Nevertheless, SRM (selected reaction monitoring) 
mode of the molecular ions with a collision energy of 5 
eV, was preferred to SIM (selected ion monitoring) 
mode in order to avoid adducts formation and improve 
sensitivity (Fig. 3). 
3.2 Comparison of Methods 
Several LC methods coupled to different detectors 
applied to the evaluation of UDCA related substances 
have been reported. However, detection limits are 
higher than mass detector, for example 0.08 µg/mL and 
400 µg/mL for fluorescence and UV detection, 
respectively. Mass spectrometry provides higher 
sensitivity with lower detection limits. 
 
 
Fig. 2  Mix standard solution of UDCA, CA, DCA, CDCA and LCA. (A): LCA (21 ng/mL) scan filter 375.3 [374.8-395.8]; (B): 
CDCA (422 ng/mL), DCA (119 ng/mL) scan filter 391.4 [390.0-391.9] and; (C): CA (207 ng/mL) scan filter 407.4 [406.9-407.9] 
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Fig. 3  Full scan mass spectra of LCA (m/z 375.35), UDCA (m/z 391.30), DCA (m/z 391.30), CDCA (m/z 391.30) and CA (m/z 
407.30). 
 
The refractive index detector is used in the USP 
method for UDCA raw material. In this sense, 
Peepliwal et al. have developed an LC method coupled 
to a refractive index detector using methanol instead of 
acetonitrile (the latter used in the USP method). 
However, up to 0.14% of UDCA related substances in 
raw material are detected with this method. Moreover, 
other methodologies as CE or TLC also present low 
sensitivity. 
The use of the mass detector provides an excellent 
sensitivity with a minimum sample amount compared 
to other methods for UDCA related substances. 
3.3 Method Validation 
3.3.1 Specificity 
This was evaluated by comparing the 
chromatograms of the blank of excipients of the 
pharmaceutical suspension with the standard solution. 
No peaks were observed in the chromatogram of the 
blank of excipients. 
3.3.1 Linearity, LOD and LOQ 
Linearity was evaluated in the range of 0.12-1.55%, 
0.06-1.06%, 0.12-2.00% and 0.03-0.30% (% w/w 
respect to UDCA) for CA, DCA, CDCA and LCA, 
respectively. The results showed good correlation 
coefficients, higher than 0.9901 (Table 1). LODs for 
CA, DCA, CDCA and LCA were 0.0007%, 0.0020%, 
0.0003% and 0.0011% (%w/w respect to UDCA), 
respectively. LOQs for CA, DCA, CDCA and LCA 
were 0.002%, 0.005%, 0.001% and 0.004% (%w/w 
respect to UDCA), respectively. RSD values for LOD 
and LOQ were lower than 2% (Table 1). The low LOD 
and LOQ values show the high sensitivity of the 
method. 
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Table 1  Linearity, LOD and LOQ and precision of UDCA related substances.  
PARAMETERS CA DCA CDCA LCA 
Linear range 
(ng/mL) 
50-625 25-425 50-800 10-115 























Precision (RSD)     
Intra-day (n = 6)     
Peak area 1.1 0.2 2.1 0.6 
Migration time 0.1 0.3 0.3 0.1 
Inter-day (n = 
12) 
    
Peak area 2.0 2.5 2.3 1.2 
Migration time 0.2 0.3 0.3 0.2 
Accuracy 
Spiked levels 




















































* %W/W respect to UDCA. ** respect to limit values. *** RSD values between brackets corresponding to n = 3. 
 
Table 2  Related substances in raw material and Suspension.  














Raw material** - - 1.1 (1.9) 0.025 (1.2) 
Suspension** - - 0.002 (0.8) 0.0003 (1.7) 
* %W/W respect to UDCA. 
** RSD values between brackets corresponding to n = 3. 
 
3.3.2 Precision and Accuracy 
Precision and accuracy results are shown in Table 1. 
The method provides good precision with RSD values 
lower than 0.3% for retention time; as for peak areas, 
RSD values were lower than 2.5%. Recovery values in 
raw material and suspension ranged from 95.0-106.3% 
to 90.6-108.9%, respectively. The results obtained for 
precision and accuracy studies were in good agreement 
with international requirements. 
3.3.3 Robustness 
All parameters were evaluated in terms of CA, DCA, 
CDCA and LCA retention factor, tailing factor and 
RSD for replicates of standard solutions (n = 6). In all 
cases, RSD values lower than 3% were obtained; this 
demonstrates that the proposed method is suitable for 
the determination of UDCA related substances.  
3.3.4 Analysis of Related Substances in Raw 
Material and pharmaceutical Suspension 
Once the validation was completed, CA, DCA, 
CDCA and LCA quantification in raw material and 
suspension was evaluated. CA and DCA have not been 
found in raw material and pharmaceutical formulations. 
The results are showed in Table 2.  
4. Conclusions 
An LC-MS/MS method for the quantification of CA, 
DCA, CDCA and LCA as related substances in UDCA 
raw material and pharmaceutical suspension was 
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developed and validated for the first time. This method 
is simple, fast, precise, exact and robust and specially, 
highly specific and sensitive allowing the use of a 
minimal sample amount. In conclusion, this method 
can be used for UDCA routine laboratory analysis and 
to monitor the stability and quality control in UDCA 
pharmaceutical formulations. 
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